

Development of a novel ADC for the treatment of glioblastoma

AimedBio Inc.



ONCOLOGY	Candidate
Product Type	Immunoglobulin Product [Antibody-Drug Conjugate]
Indication	1st indication: Glioblastoma with the fusion protein 2nd indication: Glioblastoma and bladder cancer with the target overexpression
Target	Brain tumor specific fusion protein
MoA (Mechanism of Action)	Binding to cell surface antigen → Endocytosis → Lysosomal degradation → Active payload release → Cell death
Competitiveness	First in Class <ul style="list-style-type: none"> • High brain exposure: The drug is well delivered into the brain since glioblastoma with this target protein has high density of tumor vascularization. • Superior cellular internalization and target degradation • Novel payload with high bystander effect • Survival gain confirmed in brain tumor patient-derived xenograft model
Development Stage	Candidate
Route of Administration	Parenteral - Intravenous